Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nemunaitis, J.
Right arrow Articles by Eckhardt, S. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nemunaitis, J.
Right arrow Articles by Eckhardt, S. G.
Journal of Clinical Oncology, Vol 17, Issue 11 (November), 1999: 3586-3595
© 1999 American Society for Clinical Oncology

Phase I Evaluation of ISIS 3521, an Antisense Oligodeoxynucleotide to Protein Kinase C-Alpha, in Patients With Advanced Cancer

J. Nemunaitis, J. T. Holmlund, M. Kraynak, D. Richards, J. Bruce, N. Ognoskie, T. J. Kwoh, R. Geary, A. Dorr, D. Von Hoff, S. G. Eckhardt

From the PRN Research, Inc, and Sammons Cancer Center at Baylor, Dallas; Cancer Therapy and Research Center, Institute for Drug Development, San Antonio, TX; and ISIS Pharmaceuticals, Carlsbad, CA.

Address reprint requests to John Nemunaitis, MD, Baylor University Medical Center, 3535 Worth St, Collins Building, 5th Floor, Dallas, TX 75246.

PURPOSE: To determine the maximum-tolerated dose (MTD) and pharmacologic behavior of ISIS 3521 (ISI 641A), an antisense phosphorothioate oligonucleotide to protein kinase C-alpha.

PATIENTS AND METHODS: Thirty-six patients with advanced cancer received 99 cycles of ISIS 3521 (0.15 to 6.0 mg/kg/d) as a 2-hour intravenous infusion administered three times per week for 3 consecutive weeks and repeated every 4 weeks. Plasma and urine sampling was performed during the first week of treatment and subjected to capillary gel electrophoresis to determine full-length antisense oligonucleotide in addition to chain-shortened metabolites.

RESULTS: Drug-related toxicities included mild to moderate nausea, vomiting, fever, chills, and fatigue. Hematologic toxicity was limited to thrombocytopenia (grade 1, four patients; grade 2, one patient; grade 3, one patient). There was no relationship between dose, maximum concentration of the drug (Cmax), or area under the plasma concentration versus time curve (AUC) and coagulation times or complement levels. Dose escalation was discontinued because of the attainment of peak plasma concentrations, which approached that associated with complement activation in primates. Two patients with non-Hodgkin's lymphoma who completed 17 and nine cycles of therapy achieved complete responses. The pharmacokinetic profile of ISIS 3521 revealed a short elimination half-life (18 to 92 minutes), as well as a dose-dependent decrease in clearance and dose-dependent increases in Cmax, AUC, and elimination half-life.

CONCLUSION: No dose-limiting toxicity of ISIS 3521 was identified, and clinical activity was observed. A short elimination half-life was identified, which suggests that alternate schedules with prolonged administration may be necessary for further clinical development.

ISIS 3521 (ISI 641A) is developed jointly by Isis Pharmaceuticals, Inc, and Novartis Pharma AG, Basel, Switzerland.




This article has been cited by other articles:


Home page
 JCOHome page
M. B. Thomas and J. L. Abbruzzese
Opportunities for Targeted Therapies in Hepatocellular Carcinoma
J. Clin. Oncol., November 1, 2005; 23(31): 8093 - 8108.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
K. N. Chi, E. Eisenhauer, L. Fazli, E. C. Jones, S. L. Goldenberg, J. Powers, D. Tu, and M. E. Gleave
A Phase I Pharmacokinetic and Pharmacodynamic Study of OGX-011, a 2'-Methoxyethyl Antisense Oligonucleotide to Clusterin, in Patients With Localized Prostate Cancer
J Natl Cancer Inst, September 7, 2005; 97(17): 1287 - 1296.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
T. Jelacic and D. Linnekin
PKC{delta} plays opposite roles in growth mediated by wild-type Kit and an oncogenic Kit mutant
Blood, March 1, 2005; 105(5): 1923 - 1929.
[Abstract] [Full Text] [PDF]

Home page
 Neuro OncolHome page
S. A. Grossman, J. B. Alavi, J. G. Supko, K. A. Carson, R. Priet, F. A. Dorr, J. S. Grundy, and J. T. Holmlund
Efficacy and toxicity of the antisense oligonucleotide aprinocarsen directed against protein kinase C-{alpha} delivered as a 21-day continuous intravenous infusion in patients with recurrent high-grade astrocytomas
Neuro-oncol, January 1, 2005; 7(1): 32 - 40.
[Abstract] [PDF]

Home page
 Cancer Res.Home page
H.-W. Lo, G. R. Antoun, and F. Ali-Osman
The Human Glutathione S-Transferase P1 Protein Is Phosphorylated and Its Metabolic Function Enhanced by the Ser/Thr Protein Kinases, cAMP-Dependent Protein Kinase and Protein Kinase C, in Glioblastoma Cells
Cancer Res., December 15, 2004; 64(24): 9131 - 9138.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
S. Rao, D. Watkins, D. Cunningham, D. Dunlop, P. Johnson, P. Selby, B. W. Hancock, C. Fegan, D. Culligan, S. Schey, et al.
Phase II study of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C alpha, in patients with previously treated low-grade non-Hodgkin's lymphoma
Ann. Onc., September 1, 2004; 15(9): 1413 - 1418.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
W. R. Parulekar and E. A. Eisenhauer
Phase I Trial Design for Solid Tumor Studies of Targeted, Non-Cytotoxic Agents: Theory and Practice
J Natl Cancer Inst, July 7, 2004; 96(13): 990 - 997.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
C. Monnerat, R. Henriksson, T. Le Chevalier, S. Novello, P. Berthaud, S. Faivre, and E. Raymond
Phase I study of PKC412 (N-benzoyl-staurosporine), a novel oral protein kinase C inhibitor, combined with gemcitabine and cisplatin in patients with non-small-cell lung cancer
Ann. Onc., February 1, 2004; 15(2): 316 - 323.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
S. C. Linn, R. B. West, J. R. Pollack, S. Zhu, T. Hernandez-Boussard, T. O. Nielsen, B. P. Rubin, R. Patel, J. R. Goldblum, D. Siegmund, et al.
Gene Expression Patterns and Gene Copy Number Changes in Dermatofibrosarcoma Protuberans
Am. J. Pathol., December 1, 2003; 163(6): 2383 - 2395.
[Abstract] [Full Text]

Home page
 Drug Metab. Dispos.Home page
R. S. Geary, R. Z. Yu, T. Watanabe, S. P. Henry, G. E. Hardee, A. Chappell, J. Matson, H. Sasmor, L. Cummins, and A. A. Levin
PHARMACOKINETICS OF A TUMOR NECROSIS FACTOR-{alpha} PHOSPHOROTHIOATE 2'-O-(2-METHOXYETHYL) MODIFIED ANTISENSE OLIGONUCLEOTIDE: COMPARISON ACROSS SPECIES
Drug Metab. Dispos., November 1, 2003; 31(11): 1419 - 1428.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
C. A. Burkhart, A. J. Cheng, J. Madafiglio, M. Kavallaris, M. Mili, G. M. Marshall, W. A. Weiss, L. M. Khachigian, M. D. Norris, and M. Haber
Effects of MYCN Antisense Oligonucleotide Administration on Tumorigenesis in a Murine Model of Neuroblastoma
J Natl Cancer Inst, September 17, 2003; 95(18): 1394 - 1403.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
M. A. McCracken, L. J. Miraglia, R. A. McKay, and J. S. Strobl
Protein Kinase C {delta} Is a Prosurvival Factor in Human Breast Tumor Cell Lines
Mol. Cancer Ther., March 1, 2003; 2(3): 273 - 281.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. A. Adjei, G. K. Dy, C. Erlichman, J. M. Reid, J. A. Sloan, H. C. Pitot, S. R. Alberts, R. M. Goldberg, L. J. Hanson, P. J. Atherton, et al.
A Phase I Trial of ISIS 2503, an Antisense Inhibitor of H-ras, in Combination with Gemcitabine in Patients with Advanced Cancer
Clin. Cancer Res., January 1, 2003; 9(1): 115 - 123.
[Abstract] [Full Text] [PDF]

Home page
 Nucleic Acids ResHome page
Q. Hu, M. B. Bally, and T. D. Madden
Subcellular trafficking of antisense oligonucleotides and down-regulation of bcl-2 gene expression in human melanoma cells using a fusogenic liposome delivery system
Nucleic Acids Res., August 1, 2002; 30(16): 3632 - 3641.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. W. Tolcher, L. Reyno, P. M. Venner, S. D. Ernst, M. Moore, R. S. Geary, K. Chi, S. Hall, W. Walsh, A. Dorr, et al.
A Randomized Phase II and Pharmacokinetic Study of the Antisense Oligonucleotides ISIS 3521 and ISIS 5132 in Patients with Hormone-refractory Prostate Cancer
Clin. Cancer Res., August 1, 2002; 8(8): 2530 - 2535.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. C. Cripps, A. T. Figueredo, A. M. Oza, M. J. Taylor, A. L. Fields, J. T. Holmlund, L. W. McIntosh, R. S. Geary, and E. A. Eisenhauer
Phase II Randomized Study of ISIS 3521 and ISIS 5132 in Patients with Locally Advanced or Metastatic Colorectal Cancer: A National Cancer Institute of Canada Clinical Trials Group Study
Clin. Cancer Res., July 1, 2002; 8(7): 2188 - 2192.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
G. K. Dy and A. A. Adjei
Novel Targets for Lung Cancer Therapy: Part I
J. Clin. Oncol., June 15, 2002; 20(12): 2881 - 2894.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. Mani, C. M. Rudin, K. Kunkel, J. T. Holmlund, R. S. Geary, H. L. Kindler, F. A. Dorr, and M. J. Ratain
Phase I Clinical and Pharmacokinetic Study of Protein Kinase C-{alpha} Antisense Oligonucleotide ISIS 3521 Administered in Combination with 5-Fluorouracil and Leucovorin in Patients with Advanced Cancer
Clin. Cancer Res., April 1, 2002; 8(4): 1042 - 1048.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
S. M. Luger, S. G. O'Brien, J. Ratajczak, M. Z. Ratajczak, R. Mick, E. A. Stadtmauer, P. C. Nowell, J. M. Goldman, and A. M. Gewirtz
Oligodeoxynucleotide-mediated inhibition of c-myb gene expression in autografted bone marrow: a pilot study
Blood, February 15, 2002; 99(4): 1150 - 1158.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
A. B. da Rocha, D.R.A. Mans, A. Regner, and G. Schwartsmann
Targeting Protein Kinase C: New Therapeutic Opportunities Against High-Grade Malignant Gliomas?
Oncologist, February 1, 2002; 7(1): 17 - 33.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
H. Roh, D. W. Green, C. B. Boswell, J. A. Pippin, and J. A. Drebin
Suppression of {beta}-Catenin Inhibits the Neoplastic Growth of APC-Mutant Colon Cancer Cells
Cancer Res., September 1, 2001; 61(17): 6563 - 6568.
[Abstract] [Full Text] [PDF]

Home page
 Nucleic Acids ResHome page
Z. Lei, L. Zhang, L. R. Zhang, J. Chen, J. M. Min, and L. H. Zhang
Hybrid characteristics of oligonucleotides consisting of isonucleoside 2',5'-anhydro-3'-deoxy-3'-(thymin-1-yl)-D-mannitol with different linkage modes
Nucleic Acids Res., April 1, 2001; 29(7): 1470 - 1475.
[Abstract] [Full Text] [PDF]

Home page
 GutHome page
H J N Andreyev, P J Ross, D Cunningham, and P A Clarke
Antisense treatment directed against mutated Ki-ras in human colorectal adenocarcinoma
Gut, February 1, 2001; 48(2): 230 - 237.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
P. Rojnuckarin and K. Kaushansky
Actin reorganization and proplatelet formation in murine megakaryocytes: the role of protein kinase C{alpha}
Blood, January 1, 2001; 97(1): 154 - 161.
[Abstract] [Full Text] [PDF]

Home page
 Stem CellsHome page
K.-Y. Jen and A. M. Gewirtz
Suppression of Gene Expression by Targeted Disruption of Messenger RNA: Available Options and Current Strategies
Stem Cells, September 1, 2000; 18(5): 307 - 319.
[Abstract] [Full Text]

Home page
 Clin. Cancer Res.Home page
F. Ciardiello, R. Bianco, V. Damiano, G. Fontanini, R. Caputo, G. Pomatico, Sabino De Placido, A. R. Bianco, J. Mendelsohn, and G. Tortora
Antiangiogenic and Antitumor Activity of Anti-Epidermal Growth Factor Receptor C225 Monoclonal Antibody in Combination with Vascular Endothelial Growth Factor Antisense Oligonucleotide in Human GEO Colon Cancer Cells
Clin. Cancer Res., September 1, 2000; 6(9): 3739 - 3747.
[Abstract] [Full Text]

Home page
 Nucleic Acids ResHome page
S. D. Patil and D. G. Rhodes
Influence of divalent cations on the conformation of phosphorothioate oligodeoxynucleotides: a circular dichroism study
Nucleic Acids Res., June 15, 2000; 28(12): 2439 - 2445.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. M. Gewirtz
Oligonucleotide Therapeutics: A Step Forward
J. Clin. Oncol., May 9, 2000; 18(9): 1809 - 1811.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
F. R. Khuri and J. M. Kurie
Antisense Approaches Enter the Clinic
Clin. Cancer Res., May 1, 2000; 6(5): 1607 - 1610.
[Full Text]


About
JCO		 Editorial
Roster		 Advertising
Information		 Librarians &
Institutions		 Rights &
Permissions		 PDA Services

Copyright © 1999 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online